News

Treatment of thyroid eye disease varies greatly among physicians.

Quantel Medical’s selective laser trabeculoplasty (SLT) glaucoma laser has been approved by the FDA.

Second Sight Medical Products Inc.’s retinal prosthesis system has been approved by the Centers for Medicare and Medicaid Services (CMS) for both inpatient and outpatient settings of care payments beginning Oct. 1.

Health Canada has cleared ThromboGenics NV’s treatment for symptomatic vitreomacular adhesion (VMA).

InSite Vision Inc.’s drug delivery system has received a patent from the U.S. Patent and Trademark Office.

In comparing conventional slit lamp photography with iPhone images, it was found the smartphone produces higher quality pictures and in a more economical way.

Proactive handling of pre-existing dry eye in laser vision correction patients will improve the accuracy of custom ablations and lower the risk of postoperative dry eye-related problems

Cataract surgery not only can result in a reduction of IOP, it also provides benefits for future management of glaucoma.

John of Garland, writing some 900 years ago, provided excellent advice to the young persons of his time-advice that we ophthalmologists today would be wise to heed.

Clinicians share their thoughts on the roles of a dual-acting antihistamine/mast cell stabilizer and topical ester corticosteroid in the management of seasonal allergic conjunctivitis.

Utilizing a red eye protocol can be helpful in the determination of whether conjunctivitis is allergic, viral, or bacterial.

Recent data show that although ocular allergies are common, the majority of sufferers do not seek medical help beyond over-the-counter drugs.

There are numerous methods and factors surgeons should examine for patients with age-related macular degeneration and who require cataract surgery to avoid future problems.

Patients who receive intravitreal ranibizumab (Lucentis, Genentech) for treatment of diabetic macular edema over a 3-year period achieved rapid improvements in vision and edema.

The financial feasibility of using only one laser for all procedures is a given. Arun C. Gulani, MD, takes this one step further, arguing that perhaps the future may hold cases in which use of the femtosecond laser is a necessity, becoming a standard-of-care concept.

There is a moralistic responsibility that all eye-care professionals should follow to make sure their patients choose the correct eyewear to prevent injury, especially when the patients are children.

Patients with open-angle glaucoma (OAG) had a significant reduction in IOP and did not require anti-glaucoma medications over 1 year postoperatively when micro-invasive glaucoma surgery (MIGS) was performed, according to interim results for a MIGS study group that were reported by David F. Chang, MD.

Patients with sleep apnea are more likely to develop glaucoma compared with those without the sleep condition, according to a new study.

The University of California, Los Angeles’ (UCLA) Jules Stein Eye Institute announced it has begun pursuing a long-term affiliation with the Doheny Eye Institute.

Bausch + Lomb and TheraPearl LLC have announced the creation of the Bausch + Lomb THERA°PEARL Eye Mask, a product aimed at those suffering from a variety of common ailments, including the most common type of dry eye.

InnFocus Inc. has received authorization from the FDA to begin the phase I trial of the InnFocus MicroShunt to treat open-angle glaucoma (OAG).

Ophthalmologists are nearing a crossroads with the replacement of phacoemulsification by femtosecond laser technology. New femtosecond laser technology is costly, and surgeons must decide if this technology is right for their practices, explained John Vukich, MD.

Optovue Inc. has received FDA 510 (k) clearance for its new iFusion combination system and has begun filing customer orders worldwide.

Alcon Research Ltd. has accused Mylan Inc. of seeking government approval for a drug that would infringe three of its patents for a glaucoma treatment.

Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.

Practicing reverse motivation may be just what the doctor ordered when it comes to helping staff members achieve their goals, relates columnist Dianna Graves.

Cataract surgeons wanting to tap into the premium IOL market might consider implanting toric IOLs.

Toric IOL implantation provides a reliably effective method for reducing existing astigmatism in patients undergoing cataract surgery, but careful marking of the eye to guide accurate axis alignment of the IOL is essential for achieving good outcomes, said Bonnie An Henderson, MD.